Pulmonary disease is associated with human T-cell leukaemia virus type 1c infection: a cross-sectional survey in remote Aboriginal Australian communities

Date

2021

Authors

Einsiedel, L.
Pham, H.
Talukder, M.R.R.
Liddle, J.
Taylor, K.
Wilson, K.
Jersmann, H.
Gessain, A.
Woodman, R.
Kaldor, J.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Clinical Infectious Diseases, 2021; 73(7):e1498-e1506

Statement of Responsibility

Lloyd Einsiedel, Hai Pham, Mohammad Radwanur R. Talukder, Joel Liddle, Kerry Taylor, Kim Wilson, Hubertus Jersmann, Antoine Gessain, Richard Woodman, and John Kaldor

Conference Name

Abstract

Background: The human T-cell leukemia virus type 1 (HTLV-1) subtype c is endemic to central Australia. We report the first large-scale, community-based, health survey of HTLV-1 and its disease associations in this setting. Methods: Aboriginal community residents aged >2 years in 7 remote communities were invited to do a health survey that included a questionnaire, spirometry, and clinical examination by a physician blinded to HTLV-1 status, clinical records, and spirometry results. Blood was drawn for HTLV-1 serology and proviral load (PVL). Pulmonary disease was assessed clinically and spirometrically and, where records were available, radiologically after the clinical assessment. Associations between specific diseases and HTLV-1 status were determined using logistic regression, adjusting for available confounders. Results: Overall, 579 residents (164 children aged 3–17 years; 415 adults) were examined (37.7% of the estimated resident population). HTLV-1 prevalences for children and adults were 6.1% and 39.3%, respectively. No associations were found between HTLV-1 and any assessed clinical condition among children. Chronic pulmonary disease and gait abnormalities were more common among adults with HTLV-1 infection. Adjusted odds ratios among participants with PVL ≥1000 per 105 peripheral blood leukocytes were 7.08 (95% confidence interval [CI], 2.67–18.74; P < .001), 9.81 (95% CI, 3.52–27.35; P < .001), and 14.4 (95% CI, 4.99–41.69; P < .001) for clinically defined chronic pulmonary disease, moderate-severe expiratory airflow limitation, and radiologically determined bronchiectasis/bronchiolitis, respectively, and 5.21 (95% CI, 1.50–18.07; P = .009) for gait abnormalities. Conclusions: In the first study of HTLV-1 disease associations based on community recruitment and blinded assessment, HTLV-1 infection was strongly associated with pulmonary disease and gait abnormalities.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

License

Call number

Persistent link to this record